Jeff Tyner, Ph.D, and Tyner Lab

OHSU offers select multimedia assets for use by news outlets. (Commercial use is prohibited without prior written consent.)

When using these materials, please:

  • Credit photos and video with “OHSU/Photographer name.” Photographer name, caption and usage restrictions are embedded in the image metadata.  Do not alter the content/nature of the photo. Color correction and cropping are allowed.

  • Audio and video clips should be credited to OHSU.

For more information, please contact OHSU Strategic Communications at news@ohsu.edu or 503-494-8231.

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Karen Morris, Faith Burns, and Luca Sax work in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Basil Allen works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

 Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Jeff Tyner Lab 2022
Jeff Tyner Lab 2022

Anthony Wang works in the Jeff Tyner, Ph.D., lab at the OHSU Knight Cancer Research Building on August 4, 2022. (OHSU/Christine Torres Hicks)

Tyner Lab 2022
Tyner Lab 2022

Images from Jeff Tyner, Ph.D., lab inside the OHSU Knight Cancer Research Building. (OHSU/Christine Torres Hicks)

Tyner Lab 2022
Tyner Lab 2022

Images from Jeff Tyner, Ph.D., lab inside the OHSU Knight Cancer Research Building. (OHSU/Christine Torres Hicks)

Knight Cancer Institute Research
Knight Cancer Institute Research

The Knight Cancer Institute is the only National Cancer Institute-designated Comprehensive Cancer Center between Sacramento and Seattle — an honor earned only by the nation's top cancer centers. It offers the latest treatments and technologies as well as hundreds of research studies and clinical trials. (OHSU/Christine Torres Hicks)

Jeff Tyner, Ph.D.
Jeff Tyner, Ph.D.

Jeffrey Tyner, Ph.D., co-led new research that zeros in on a potential drug targeted to stop acute myeloid leukemia. (OHSU/Christine Torres Hicks)

Jeff Tyner, Ph.D.
Jeff Tyner, Ph.D.

Jeffrey Tyner, Ph.D., co-led new research that zeros in on a potential drug targeted to stop acute myeloid leukemia. (OHSU/Christine Torres Hicks)